Results 141 to 150 of about 4,535 (170)

Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study

The Lancet Regional Health - Western Pacific, 2023
Dechang Chen, Lun-Xiu Qin, Quanhong Zhou   +2 more
exaly  

Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID‐19: A rapid review and meta‐analysis

Journal of Medical Virology, 2023
Bahman Amani, Behnam Amani
exaly  

Paxlovid for hospitalized COVID-19 patients with chronic kidney disease

Antiviral Research, 2023
Zhenyuan Li, Jiayi Yan
exaly  

Postmarketing Reporting of Paxlovid‐Related Dysgeusia: A Real‐World Pharmacovigilance Study

Otolaryngology - Head and Neck Surgery, 2023
Ashton Lehmann
exaly  

Proxalutamide for the treatment of COVID‐19 rebound following Paxlovid treatment: Report of four cases and review of the literature

Journal of Clinical Laboratory Analysis, 2023
Dawei Yang
exaly  

Cholesterol-lowering Drugs for High-Risk Hypercholesterolemia Patients with COVID-19 While on Paxlovid™ Therapy

Future Virology, 2022
Petri Kovanen, Alpo Vuorio, Frederick Raäl   +2 more
exaly  

Paxlovid (nirmatrelvir/ritonavir).

WMJ : official publication of the State Medical Society of Wisconsin, 2022
Kristin, Busse, Abir T, El-Alfy
openaire   +1 more source

Paxlovid for a patient on DOAC

2022
openaire   +1 more source

Paxlovid for a Patient on a DOAC

2022
openaire   +1 more source

Barriers to Worldwide Access for Paxlovid, a New Treatment for COVID-19

Open Forum Infectious Diseases, 2022
Andrew M Hill, Junzheng Wang, Toby Pepperrell   +2 more
exaly